MissionIR's  Instablog

Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
My blog:
MissionIR Blog
  • Actinium Pharmaceuticals, Inc. (ATNM) Presenting At 16th Annual BIO CEO & Investor Conference Today 0 comments
    Feb 11, 2014 2:08 PM | about stocks: ATNM

    Actinium Pharmaceuticals, a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, is presenting a corporate today at 1:30 pm ET at the 16th Annual BIO CEO & Investor Conference.

    Today's presentation will be held at The Waldorf-Astoria Hotel: Conrad Room, New York, NY. There will also be a webcast available at: www.veracast.com/webcasts/bio/ceoinvesto.../.

    A replay of the webcast will also be archived on Actinium's website for 90 days following the presentation.

    According to the American Cancer Society, half of all men and one third of all women will develop at least one form of cancer during their lifetime. There are more than 1.5 million new cancer cases per year in the U.S. and nearly 12.7 million worldwide, excluding non-melanoma skin cancers. Worldwide sales of biopharmaceutical products for treating cancer are approximately $50 billion per year, with U.S. sales being approximately half of that. Biopharmaceutical cancer treatments include a variety of drugs, but two categories predominate: cytotoxic chemotherapy and targeted therapies. Other approaches (e.g., hormonal therapy, phototherapy, cryotherapy, etc.) are used less frequently.

    Actinium Pharmaceuticals is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. The company's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies.

    For more information on Actinium Pharmaceuticals, its biopharmaceutical innovations, and their progress, please visit: actiniumpharmaceuticals.com

    MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com

    Stocks: ATNM
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.